FIELD: chemistry; pharmaceutics.
SUBSTANCE: group of inventions relates to chemistry and pharmaceutical industry, namely: to an ion channel blocker (or a pharmaceutically acceptable salt thereof) selected from 145 compounds having amino acid sequences SEQ ID NO: 1–145 in sequence listing; to a method for synthesis thereof; to a composition for treating an inflammatory condition or disorder comprising the disclosed ion channel blocker and a carrier, excipient or excipient; to applications of said ion channel blocker for inhibiting or reducing inflammation and for treating an inflammatory condition or disorder. Also disclosed are versions of the ion channel blocker having the amino acid sequence SEQ ID NO: 3, 30, 95, 97, 101 or 103, in which pairs of cysteine (C) residues such as 6C and 27C, 12C and 32C, 16C and 34C, participate in formation of a disulphide bond.
EFFECT: group of inventions provides novel ion channel blockers Kv1_3.
13 cl, 11 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PLATFORM BASED ON CYSTEINE KNOT SCAFFOLD | 2016 |
|
RU2770384C2 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
| SWINE G-CSF VARIANTS AND APPLICATION THEREOF | 2018 |
|
RU2823074C2 |
| PEPTIDE HAVING ACTIVITY OF HUMAN SLURP-1 PROTEIN AND ITS APPLICATION FOR SUPPRESSION OF GROWTH OF CARCINOMA AND GLIOMA, PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF GROWTH OF CARCINOMA AND GLIOMA, AND METHOD FOR SUPPRESSION OF GROWTH OF CARCINOMA AND GLIOMA USING THE SPECIFIED PEPTIDE | 2022 |
|
RU2792364C1 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| ADAM9-BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2783619C2 |
| METHODS AND COMPOSITIONS FOR TREATMENT OF GASTROINTESTINAL DISORDERS | 2014 |
|
RU2763796C2 |
| PEPTIDE IMMUNOGENS TARGETING INTERLEUKIN 6 (IL-6) AND COMPOSITIONS THEREOF FOR IMMUNOTHERAPY OF DISEASES AFFECTED BY IMPAIRED IL-6 REGULATION | 2019 |
|
RU2780161C1 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
